Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population

Armed with a new chief following the unexpected passing of longtime CEO Thomas Neff last year, FibroGen is off to the races with its controversial AstraZeneca-partnered anemia drug. The FDA has accepted the company’s application to market the oral therapy — which is positioned to replace the standard of care — in patients with chronic kidney disease regardless of dialysis status.